[1] Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice[J]. Mayo Clin Proc, 2008, 83(9): 1032-1045.
[2] Ruggiero LS. Bisphosphonate-related osteonecrosis of the jaw: an overview[J]. Ann N Y Acad Sci, 2011, 1218: 38-46.
[3] Graham DY. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates[J]. Dig Dis Sci， 2002, 47(8):1665-1678.
[4] Watts NB，Diab DL． Long-term use of bisphosphonates in osteoporosis[J]． J Clin Endocrinol Metab，2010，95（4）: 1555-1565.
[5] Bilezikian JP. Osteonecrosis of the jaw—do bisphosphona-tes pose a risk [J] ? N Engl J Med, 2006, 355(22): 2278-2281.
[6] Bolland MJ, Grey AB, Horne AM, et al. Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months[J]. J Bone Miner Res, 2008, 23(8): 1304-1308.
[7] Bi Y, Gao Y, Ehirchiou D, et al. Bisphosphonates cause osteonecrosis of the jaw-like disease in mice[J]. Am J Pathol, 2010, 177(1): 280-290.
[8] Yamashita J, McCauley LK, Van Poznak C. Updates on osteonecrosis of the jaw[J]. Curr Opin Support Palliat Care, 2010, 4(3): 200-206.
[9] Vescovi P, Merigo E, Meleti M, et al. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients[J]. J Oral Pathol Med, 2012, 41(3): 214-221.
[10] Pautke C, Kreutzer K, Weitz J, et al. Bisphosphonate related osteonecrosis of the jaw: a minipig large animal model [J]. Bone, 2012, 51(3): 592-599.
[11] Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update[J]. J Oral Maxillofac Surg, 2009，67(5 Suppl): 2-12.
[12] 贺捷，邱蔚六． 二膦酸盐与颌骨骨坏死[J]． 中国口腔颌面外科杂志，2010,8(4):370-375.
[13] Shenker NG, Jawad AS. Bisphosphonates and osteonecrosis of the jaw[J]. Rheumatology (Oxford), 2007, 46(7): 1049-1051.
[14] Dunford JE, Thompson K，Coxon FP. et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates[J]. J Pharmacol Exp Ther, 2001, 296(2): 235-242.
[15] Bonacina R, Mariani U, Villa F, et al. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients[J]. J Can Dent Assoc,2011,77:b147.
[16] Suleman YF, Meer S, Lurie R, et al. Bisphosphonate-induced osteonecrosis of the jaws: review, clinical implications and case report[J]. Head Neck Pathol, 2007, 1(2): 156-164.
[17] Mavrokokki A, Cheng A, Stein B, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia[J]. J Oral Maxillofac Surg, 2007, 65(3):415-423.
[18] Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association[J]. Med J Aust, 2005, 182(8): 413-415.
[19] Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-center experience in 303 patients[J]. Br J Haematol, 2006, 134(6):620-623.
[20] Christodoulou C, Pervena A, Klouvas G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone[J]. Oncology, 2009, 76(3): 209-211.
[21] Herbozo PJ, Briones DL, Ferres AJ, et al. Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws[J]. J Oral Maxillofac Surg, 2007, 65(8): 1650-1654.
[22] Han JW. Bisphosphonate related osteonecrosis of the jaws: report of two cases[J]. Imaging Sci Dent, 2011, 41(3): 129-134.
[23] Favus MJ. Diabetes and the risk of osteonecrosis of the jaw [J]. J Clin Endocrinol Metab, 2007, 92(3):817-818.
[24] Sonis ST, Watking BA, Lyng GD, et al. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients[J]. Oral Oncol, 2009, 45(2): 164-172.
[25] Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study[J]. J Oral Maxillofac Surg, 2008, 66(4): 625-631.
[26] Migliorati CA, Schubert MM, Peterson DE, et al.Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy [J]. Cancer, 2005, 104(1):83-93.
[27] Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research[J]. J Bone Miner Res 2007, 22(10):1479-1491.
[28] Stresing V, Fournier PG, Ballahcene A, et al. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase [J]. Bone, 2011,48(2): 259-266.
[29] 黄婉兰,林英城．双膦酸盐抗血管形成机制研究进展[J]．国际肿瘤学杂志，2010,37（11）：831-835.
[30] Hewitt C, Farah SC. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review[J]. J Oral Pathol Med, 2007, 36(6): 319-328.
[31] Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment[J]. J Oral Maxillofac Surg, 2005, 63(11): 1567-1575.
[32] Sedghizadeh PP, Kumar SK, Gorur A, et al. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy[J]. J Oral Maxillofac Surg, 2008, 66(4): 767-775.
[33] Otto S, Hafner S, Mast G, et al. Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle[J]? J Oral Maxillofac Surg, 2010, 68(5):1158-1161.
[34] Otto S, Schreyer C, Hafner S, et al. Bisphosphonate-related osteonecrosis of the jaws-characteristics, risk factors, clinical features, localization and impact on oncological treatment[J]. J Craniomaxillofac Surg, 2012, 40(4): 303-309.
[35] Hokugo A, Christensen R, Chung EM, et al. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats [J]. J Bone Miner Res, 2010, 25(6):1337-1349.
[36] Holick MF. Vitamin D deficiency[J]. N Engl J Med, 2007, 357(3): 266-281.
[37] Ficarra G, Beninati F. Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects[J]. Head Neck Pathol, 2007, 1(2): 132-140.
[38] Kademani D, Koka S, Lacy MQ, et al. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy[J]. Mayo Clin Proc, 2006, 81(8): 1100-1103.
[39] Kikuiri T, Kim I, Yamaza T, et al. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice[J]. J Bone Miner Res, 2010, 25(7): 1668-1679.
[40] Handschel J, Meyer U. Infection, vascularization, remodelling--are stem cells the answers for bone diseases of the jaws [J]? Head Face Med, 2011, 7:5.
[41] Luo JZ, Xiong F, Al-Homsi AS, et al. Human BM stem cells initiate angiogenesis in human islets in vitro [J]. Bone Marrow Transplant, 2011, 46(8): 1128-1137.
[42] Romeo U, Galanakis A, Marias C, et al. Observation of pain control in patients with bisphosphonate-induced osteonecrosis using low level laser therapy: preliminary results [J]. Photomed Laser Surg, 2011, 29(7): 447-452.
[43] Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment[J]. J Oral Maxillofac Surg, 2007, 65(12): 2397-2410.
|